Antibiotic crisis grows while drug companies make lifestyle meds
South Korean models promote Cialis, a drug made by Eli Lilly that claims to make men potent for up to 36 hours, dosage depending. Credit: AAP/Yonhap News.
Antibiotics for acute infections are a pillar of medicine, but doctors say the pillar is crumbling as pharmaceutical companies neglect antibiotic development and instead chase massive profits from chronic illnesses and lifestyle diseases.
With a surge in often lethal infections that are resistant to existing antibiotics coinciding with a drastic shortage of new antibiotics in development, Professor Laura Piddock, of the University of Birminghams School of Immunity and Infection, has called for a global alliance to find a new generation of this most staple of medicines.
Writing in The Lancet Infectious Diseases edition last week, Professor Piddock argues that the drug industry will be shooting itself in the foot if it continues its myopic focus on the most lucrative drugs: pharmaceutical companies need to recognise that many expensive medicines in their portfolio and in development might by useless if patients succumb to fatal infections. Therefore, their return on investment for products to treat cancer or chronic diseases depends, in part, on effective treatment of infections.
Professor Piddock, who is also the President of the British Society for Antimicrobial Chemotherapy, writes that while public attention is often focused on access to exotic new drugs for diseases such as cancer, it is antibiotics that routinely keep cancer patients alive. The same is true for people aged over 65 whose immune systems are naturally waning yet often find themselves having medical procedures, Professor Piddock writes. For such people, antibiotics are an integral and routine part of treatment.
Yet, this routine treatment is increasingly failing as infectious bacteria become resistant to antibiotics. The World Health Organization (WHO) warns that many infectious diseases risk becoming uncontrollable.
Even as the antibiotic pipeline is drying up, discovering new ones is much more difficult than it used to be, said Professor Ken Harvey, Adjunct Senior Lecturer of Public Health at La Trobe University.
The low-hanging fruits disappeared. Penicillin came from a mould that floated in through the window of Alexander Flemings laboratory. Streptomycin came from a mould on a cantaloupe. The easy stuff has been done, and its more difficult to develop new drugs, Professor Harvey said.
Another really big problem is that the industry really hasnt put the money into it in recent years, and theres a reason for that: theres not a good return on investment with antibiotics when you compare them to drugs for diabetes, heart disease these are chronic, lifelong diseases that need lifelong medication the problem is that antibiotics are basically used in short courses to treat infections, Professor Harvey said
They [the drug companies] say theres no return on investment, and thats rather ironic because classically thats been the problem of neglected diseases in the third world where poor people dont have the money to pay for medicines, and so they havent researched tropical diseases, etcetera, but now its definitely come home to bite developed countries with antibiotics, Professor Harvey said.
The relatively few new antibiotics suitable for resistant organisms are often used very sparingly to avoid the bugs finding ways to overcome them and this practice compounds the commercial disincentive to develop such medicines, Professor Harvey said.
Theres no profit in it, and therefore the research has dried up, but meanwhile bacterial resistance has increased inexorably and theres still a lot of inappropriate use of antibiotics out there. There are now some organisms in hospital practice that are resistant to everything weve got and patients are dying, but they tend to be immuno-suppressed patients, critically ill, with lots of other things wrong with them. We are running out of antibiotics the germs are doing well and the chemists have not given us what we should have, Professor Harvey said. The profit orientated approach, which has been quite successful for chronic diseases because theres money in it, is not working for antibiotics.
Developing medicines for ongoing conditions is often so profitable that the drug industry sometimes exaggerates the incidence of diseases requiring ongoing medication or even invents diseases to suit, Professor Harvey said.
Disease mongering its called, said Professor Harvey. The focus were trying to bring the industry to is to produce drugs that are genuinely needed rather than producing drugs that arent needed, but its more profitable to produce the 15th anti-depressant or the 27th anti-hypertensive than it is to produce a new antibiotic at the moment, because you can market them aggressively and try to make out that new is better than old when often it isnt.
Meanwhile, antibiotic-resistant superbugs are killing an estimated 500,000 people each year just in Europe and the US, according to Matthew Cooper, the Professor of Molecular Bioscience at the University of Queensland. With each patient who gets a superbug staying in an ICU [intensive care unit] upwards of a week, its costing the US alone upwards of $20 billion a year its an enormous cost to society, said Professor Cooper, who is working to gather the figures for Australia.
Despite the toll of our failing antibiotics, it would be unrealistic to expect pharmaceutical companies to pull their R&D money out of more lucrative drugs aimed at patients who need to take them for years. We cant change capitalist behaviour; we live in a capitalist society, and drug companies need to make money to survive. What we can do, however, is look at different types of business models, he said.
In addition to hybrid models of public-private partnerships, we could use patent extension [for new antibiotics] so they have five more years before it becomes generic, or if the government subsidised the cost of Phase III trials [randomised multi-centre trials on large numbers of patients], then not just big pharma companies but smaller biotechs could afford to develop antibiotics, Professor Cooper said. When a new drug is launched it will not only save millions of lives, it will save billions of dollars so it makes a lot of sense to look at different types of business models and development models that will encourage biotechs to invest in antibiotics again.
A global alliance to develop new antibiotics was vital but not unprecedented, Professor Cooper said. Weve seen a couple of global alliances make a huge impact polio vaccine, small pox. HIV/AIDS is a good example because there was a fantastic lobbying alliance by the gay community in America and right now weve got great drugs for HIV/AIDS and people dont actually die in Africa very much anymore from HIV, they die from TB tuberculosis so when we actually behave in an egalitarian manner and put our resources together we can make a big difference, he said.
This story is published courtesy of the The Conversation (under Creative Commons-Attribution/No derivatives).
Source: The Conversation
- Kids born with HIV growing up well Apr 21, 2011 | not rated yet | 0
- Home-computer users at risk due to use of 'folk model' security May 24, 2011 | not rated yet | 0
- Commonly prescribed antibiotic may not work best against MRSA skin infections in children Aug 16, 2011 | not rated yet | 0
- Antibiotic dangers trap bees in a Catch 22 Nov 02, 2011 | not rated yet | 0
- New knowledge will boost fight against superbug Sep 07, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
(AP)—Government health officials are investigating several health problems reported with potentially contaminated medications made by a Tennessee specialty pharmacy.
Diseases, Conditions, Syndromes 19 hours ago | not rated yet | 0
(HealthDay)—Comorbid conditions often accompany alopecia areata, according to a study published online May 22 in JAMA Dermatology.
Diseases, Conditions, Syndromes 20 hours ago | not rated yet | 0
(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.
Diseases, Conditions, Syndromes 21 hours ago | not rated yet | 0
Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.
Diseases, Conditions, Syndromes May 24, 2013 | not rated yet | 0
The World Health Organization voiced deep concern Thursday over the SARS-like virus that has killed 22 people in less than a year, saying it might potentially spread more widely between humans.
Diseases, Conditions, Syndromes May 24, 2013 | 5 / 5 (1) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
3 hours ago | not rated yet | 4
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
22 hours ago | 3.7 / 5 (3) | 3 |
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
3 hours ago | not rated yet | 1
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
19 hours ago | 3 / 5 (2) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
22 hours ago | 5 / 5 (5) | 0 |
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
3 hours ago | not rated yet | 0